ClinicalTrials.gg
RecruitingNCT00412594Updated Jun 11, 2026

Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

A Phase 2 interventional study of Cladribine and Laboratory Biomarker Analysis in Hairy Cell Leukemia and Recurrent Hairy Cell Leukemia, sponsored by M.D. Anderson Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-11.

Sponsored by M.D. Anderson Cancer Center · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 2 years 6 months after the study started (first participant enrolled Jun 2004, registered Dec 2006).
  • Started Jun 2004; still recruiting 22 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies testing rituximab in Leukemia, Hairy Cell — 1 open to participants now, 3 under way, none of them phase 3. Rituximab · Leukemia, Hairy Cell.

Planned enrollment
2nd of 13
150 · median 20
Started
2004
with 1 other
Phase 2
8 of 13
1 open now
Registered
4th of 13
by date
Lead sponsor
1 of 13
M.D. Anderson Cancer Center

Among the 13 studies testing rituximab in Leukemia, Hairy Cell, this one is the 2nd largest by planned enrollment, is one of 2 that started in 2004, is one of 8 in phase 2, and was the 4th registered.

Leukemia, Hairy Cell

237 studies on the registry are indexed under Leukemia, Hairy Cell; 18 are open to participants now.

Browse Leukemia, Hairy Cell studies →

Open to participants now

1 of the 13 studies testing rituximab in Leukemia, Hairy Cell is open now, in 1 country.

By country, each count listing its studies:

Where they have run

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 14 Leukemia, Hairy Cell studies recruiting now, 12 (86%) set no upper age limit and none (0%) stop at 75 or younger; none take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing rituximab in Leukemia, Hairy Cell, or all of them as a file.
02

Study summary

This phase II trial studies the side effects and how well cladribine and rituximab work in treating patients with hairy cell leukemia. Drugs used in chemotherapy, such as cladribine, work in different ways to stop the growth of cancer cells either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as rituximab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cladribine together with rituximab may kill more cancer cells.

Read the detailed description

PRIMARY OBJECTIVES:

I. To demonstrate the efficacy in achieving complete response of combination of cladribine administered intravenously over 2 hours for 5 days followed by rituximab weekly for 8 weeks in patients with untreated or previously treated hairy cell leukemia.

II. To examine the efficacy of rituximab to eradicate minimal residual disease (MRD) after cladribine therapy (as assessed by immunophenotyping of bone marrow and peripheral blood).

III. To examine the effect of addition of rituximab to cladribine on the long term disease-free (DFS) and overall survival (OS) (as compared with historical controls).

IV. To evaluate potential predictors of outcome including molecular and flow evaluations of MRD, as well as other potential molecular predictors such as v-raf murine sarcoma viral oncogene homolog B1 (BRAF).

OUTLINE:

Patients receive cladribine intravenously (IV) over 2 hours once daily (QD) on days 1-5 and rituximab IV once weekly for 8 weeks beginning on day 28 in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for 1 year.

03

Conditions studied

  • Hairy Cell Leukemia
  • Recurrent Hairy Cell Leukemia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years and older
  • Diagnosis of hairy cell leukemia (HCL) established by bone marrow examination
  • Patients with disease are eligible if they have had no more than one prior therapy
  • Women of must use (oral contraceptive, barrier, abstinence or any other acceptable method) for the duration of the study
  • Performance status =\< 3
  • Creatinine less than or equal to 2.0 unless related to the disease
  • less than or equal to 3.0
  • Transaminases less than or equal 3 x unless related to the disease
  • No prior agent in the 4 weeks prior to initiation of therapy

Exclusion criteria

Exclusion Criteria:

  • Unable or unwilling to sign the consent form
  • Known infection with (HIV), or C
  • Presence of active infection
  • Presence of central nervous system (CNS)
  • classification III or IV heart disease
  • Prior chemotherapy (last 4 weeks)
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Treatment (cladribine and rituximab)

    Patients receive cladribine IV over 2 hours QD on days 1-5 and rituximab IV once weekly for 8 weeks beginning on day 28 in the absence of disease progression or unacceptable toxicity.

    Drug: Cladribine · Other: Laboratory Biomarker Analysis · Biological: Rituximab

Interventions

  • Given IV

    Also known as: 2-CdA, 2CDA, CdA, Cladribina, Leustat, Leustatin, Leustatine, RWJ-26251

  • OtherLaboratory Biomarker Analysis

    Correlative studies

  • BiologicalRituximab

    Given IV

    Also known as: ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima

06

What researchers measure

Primary outcomes

  1. Efficacy of rituximab on achievement of complete response after therapy with cladribine

    Defined as the absence of hairy cells in the bone marrow or the presence of less than 1 percent atypical cells and the disappearance of all evidence of hairy cell leukemia on physical examination. Monitored using the method of Thall, Simon, Estey as extended by Thall and Sung.

    Time frame: At 12 weeks

  2. Monitoring the related toxicity for the therapy Grade 3-4

    Monitored using the method of Thall, Simon, Estey as extended by Thall and Sung.

    Time frame: Up to 1 year

  3. Efficacy of rituximab in eradication of minimal residual disease after cladribine therapy, assessed by immunophenotyping of bone marrow and peripheral blood

    The method of Thall, Simon, Estey as extended by Thall and Sung will be used for efficacy and safety monitoring.

    Time frame: Up to 4 weeks after the last dose of rituximab

  4. Efficacy of rituximab on prolongation of event-free survival

    Time frame: Up to 1 year

  5. Efficacy of rituximab on prolongation of overall survival

    Time frame: Up to 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Ravandi F, O'Brien S, Jorgensen J, Pierce S, Faderl S, Ferrajoli A, Koller C, Challagundla P, York S, Brandt M, Luthra R, Burger J, Thomas D, Keating M, Kantarjian H. Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia. Blood. 2011 Oct 6;118(14):3818-23. doi: 10.1182/blood-2011-04-351502. Epub 2011 Aug 5. PubMed 21821712 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2004 (actual). Primary completion is estimated for Jun 2027, 276 months after the start.

Of 22 phase 2 interventional studies under Leukemia, Hairy Cell, half reached primary completion within 111 months of starting (the median), counting those still running; a quarter within 64 and three quarters within 149. This study's planned 276 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2006
First posted
Dec 18, 2006
StartActual
Jun 10, 2004
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Jun 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00412594
Responsible party
Sponsor
First posted
Dec 18, 2006
Start date
Jun 10, 2004
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Jun 11, 2026

Study contacts

Farhad Ravandi-Kashani
Contact
fravandi@mdanderson.org
713-792-7305
Farhad Ravandi-Kashani
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cladribine · Rituximab

Start the discussion